Xenetic Biosciences Inc Total Assets
Xenetic Biosciences Inc total assets. Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) holds total assets worth $6.97 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see XBIO stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Xenetic Biosciences Inc (2011–2025)
Total assets of Xenetic Biosciences Inc from 2011 to 2025. This chart illustrates how Xenetic Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Xenetic Biosciences Inc for real-time trading data and today's change.
Xenetic Biosciences Inc - Asset Composition Analysis
Xenetic Biosciences Inc Total Assets Breakdown (December 2025)
Xenetic Biosciences Inc total assets breakdown as of December 2025. Xenetic Biosciences Inc's total assets of $6.97 Million consist of 96.3% current assets and 3.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Xenetic Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Xenetic Biosciences Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xenetic Biosciences Inc's current assets represent 96.3% of total assets in 2025, an increase from 4.5% in 2011.
- Cash Position: Cash and equivalents constituted 94.3% of total assets in 2025, up from 4.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Xenetic Biosciences Inc Competitors by Total Assets
Key competitors of Xenetic Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Xenetic Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.43 | 5.93 | 18.35 |
| Quick Ratio | 7.43 | 5.93 | 18.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.76 Million | $4.45 Million | $19.46 Million |
Xenetic Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Xenetic Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 21.2% |
| Total Assets | $8.36 Million |
| Market Capitalization | $4.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xenetic Biosciences Inc's assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Xenetic Biosciences Inc's assets grew by 21.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xenetic Biosciences Inc (2011–2025)
The table below shows the annual total assets of Xenetic Biosciences Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.36 Million | +21.19% |
| 2024-12-31 | $6.90 Million | -34.92% |
| 2023-12-31 | $10.61 Million | -27.96% |
| 2022-12-31 | $14.72 Million | -25.71% |
| 2021-12-31 | $19.82 Million | +50.35% |
| 2020-12-31 | $13.18 Million | -38.83% |
| 2019-12-31 | $21.55 Million | +49.31% |
| 2018-12-31 | $14.43 Million | -24.70% |
| 2017-12-31 | $19.16 Million | -8.63% |
| 2016-12-31 | $20.97 Million | +24.04% |
| 2015-12-31 | $16.91 Million | +3.63% |
| 2014-12-31 | $16.32 Million | -16.18% |
| 2013-12-31 | $19.47 Million | -23.28% |
| 2012-12-31 | $25.37 Million | +11302.81% |
| 2011-12-31 | $222.50K | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatmen… Read more